Very simple. The phrase on a message board of "2 years of continuous safety data plus" is not judged to be acceptable by educated experienced professional scientists who are still waiting for scientific proof requested at the end of Reach2HD Phase II. A greater effort should be provided by those who can scrape up evidence, if it exists, to warrant the existence of such a phrase.
To my knowledge Prana has never run a clinical trial with PBT2 dosing the SAME patients CON- TINUOUSLY for a period of two years plus. Useless nonproductive "GAP" is Prana's middle name.
PBT Price at posting:
5.8¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)